New One-Day Treatment For Early-Stage Breast Cancer

DAYTONA BEACH, Fla., May 17, 2017 Florida Hospital Memorial Medical Center now offers a one-day treatment option for patients with early-stage breast cancer.

Called the Xoft Axxent Electronic Brachytherapy (eBx) System, this specialized equipment can be used to treat cancer anywhere in the body, including gynecological cancers and nonmelanoma skin cancer. However, one of the most exciting uses is how this technology revolutionizes early-stage breast cancer treatments at Florida Hospital Memorial Medical Center.

Clinically described as intraoperative radiation therapy (IORT), this advanced technology provides many benefits to early-stage breast cancer patients, including fewer treatments and reduced costs.

Some women, such as those who live in rural areas, women who are working, and women who are caretakers for their families, may find traditional breast cancer treatment difficult because it requires them to travel to the hospital for radiation five days a week, for a span of about six to eight weeks. That's really hard for a lot of women, said Dr. Ronald Rasmussen, Florida Hospital Memorial Medical Center general surgeon. Because IORT only requires one dose of radiation, patients can typically return to their normal daily activities within days, instead of weeks like traditional radiation treatment.

With IORT, radiation is delivered from inside the breast, instead of externally with traditional external beam radiation therapy.

During the lumpectomy procedure, radiation oncologists and breast cancer surgeons work together to deliver a full, concentrated dose of radiation, so the patient may have the surgical and radiation portions of their breast cancer treatment in the same day.

After the lumpectomy is performed, physicians use a miniaturized x-ray source, which is inserted into a flexible balloon-shaped applicator, and then temporarily placed inside the lumpectomy cavity. A full course of radiation is then administered in a single dose, lasting as little as eight minutes and directly targeting cancer cells.

From inside the breast, IORT targets cancer cells and spares healthy tissue, such as the heart, lungs, and ribs, said Dr. Shravan Kandula, Florida Hospital Memorial Medical Center radiation oncologist. In addition, two major studies have shown IORT is not only effective, but it also has fewer side effects than traditional radiation, making it a viable treatment option for appropriate patients.

A growing body of favorable clinical data supports the use of IORT in candidates meeting specific selection criteria. iCAD is currently conducting one of the largest IORT clinical studies to date using the Xoft System, which compares Xoft IORT to traditional external beam radiation therapy.

About Florida Hospital Memorial Medical Center

Florida Hospital Memorial Medical Center is a member of Adventist Health System, a faith-based health care organization with 45 hospital campuses and 8,200 licensed beds in nine states, serving more than 5 million patients annually. With a mission to extend the healing ministry of Christ, Florida Hospital Memorial Medical Center includes the 327-bed facility in Daytona Beach, as well as Florida Hospital Oceanside with 80 beds in Ormond Beach. Florida Hospital Memorial Medical Center and Florida Hospital Oceanside are two of the seven Florida Hospitals in Flagler, Lake and Volusia counties that composes the Florida Hospital Central Florida Division - North Region. As the largest hospital system in the area, the Florida Hospital Central Florida Division - North Region has 1,226 beds and more than 7,800 employees. For more information about Florida Hospital Memorial Medical Center, visit www.floridahospitalmemorial.org.

About Xoft Axxent Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer-aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft Axxent Electronic Brachytherapy (eBx) System delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Companys ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Companys filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.